New certifications follow Dräger's previous ATO certification for a critical care ventilator Dräger Evita V800/V600 and Babylog VN800 family of...
Investment Powers the Debut of Pyxa: A Groundbreaking Platform for 3D Spatial Biology Research BOSTON, Feb. 11, 2025 /PRNewswire/ -- Stellaromics,...
Collaboration Aims to Develop First Intranasal Therapy for Mild Traumatic Brain Injury Aka Concussion, Establishing a Comprehensive Test-to-Treat PlatformSARASOTA, Fla....
SEATTLE and VANCOUVER, British Columbia, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical...
Collaboration to provide Firefly with the technical resources to help further unleash the power of its FDA-cleared BNA™ platform For...
MIAMI, Feb. 10, 2025 /PRNewswire/ -- The Digital Safety Alliance (DSA) is proud to celebrate its one-year anniversary with the...
HOUSTON, TEXAS, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) the leader...
No Safety Concerns Identified by DSMC in the ORCA-OL Long-Term Exposure Trial Achieve Reiterates Planned Cytisinicline NDA Submission in Q2...
February 10, 2025 Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis Underscores unmet need for...
Financing led by Nantahala Capital and ADAR1 Partners, LP with participation from new and existing healthcare-focused institutional investors $15 million...
Trial Met the Primary Endpoint and Provides Evidence of GTx-104 Clinical Benefit Compared to Orally Administered Nimodipine New Drug Application...
BRAINTREE, Mass., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced that it has entered into...
Company Poised to Enter Booming Bispecific Antibody Market Amid Growing Pharma Interest Providence, RI, Feb. 10, 2025 (GLOBE NEWSWIRE) --...
Successful detection of brain metastases using RAD 101 (18F-Pivalate) in a novel multiparametric imaging methodology (PET-mpMRI) study across 22 patients.All...
– Funds to be used primarily to advance development of ATH434 in Parkinsonian Disorders – – Capital raising was strongly...
Glen Rock, N.J., Feb. 10, 2025 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (“RespireRx” or the “Company”), a leader in the...
NEW YORK, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new...
Two presentations at ISC build on a growing body of data demonstrating the value of AI-powered portable MR images in...
BETHESDA, Md., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology...
VANCOUVER, British Columbia, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO), a biopharmaceutical company advancing...